Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Azacitidine in lower-risk myelodysplastic syndromes.

    ... 50% in lower-risk patients; most patients who achieved transfusion independence were also lower-risk. A further retrospective study reported ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going

    ... clinical benefit. Anti-complement treatment allowed transfusion independence in at least half of PNH patients receiving eculizumab, with ...

    Research Article last updated 05/22/2014 - 8:24am.

  3. Eltrombopag and improved hematopoiesis in refractory aplastic anemia

    ... were clinically significant changes in blood counts or transfusion independence . Patients with a response continued to receive eltrombopag. ...

    Research Article last updated 07/31/2012 - 2:24pm.

  4. Engraftment of heavily transfused patients with severe aplastic anemia with a fludarabine-based regimen

    ... in total, 77 patients showed durable engraftment and transfusion independence , and 64 are alive at a median time of 49 months with an ...

    Research Article last updated 03/05/2013 - 8:04am.

  5. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 03/05/2013 - 9:38am.

  6. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 10/02/2012 - 9:57am.

  7. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

    ... (66%) patients on treatment for over 12 months achieved transfusion independence on eculizumab. The mean transfusion requirement reduced by ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    ... but not with achievement or duration of 26-week transfusion independence response. In a multivariate analysis, p53-positive ...

    Research Article last updated 04/23/2014 - 12:26pm.

  9. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

    ... need for early trial termination. Duration of platelet transfusion independence, duration of response, overall survival, leukaemia-free survival, ...

    Research Article last updated 02/21/2017 - 9:49am.

  10. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... remission, red blood cell [RBC] or platelet transfusion independence [TI], or hematologic improvement, (IWG 2006) was attained by 36% ...

    Research Article last updated 12/09/2015 - 8:56am.